Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Bioprinting, Biofabrication, Organoids & Organs-on-Chips Asia 2022

Min Jae Song 's Biography

Min Jae Song , Staff Scientist, National Center for Advancing Translational Sciences (NCATS)

Dr. Song earned B.S. in 2004 and M.S. in 2006 from Mechanical Engineering of Hanyang University in South Korea and Texas A&M University, focusing on soft tissue mechanics. Dr. Song received Ph.D from Biomedical Engineering at Case Western Reserve University in 2012, focused on developing multi-physics computational prediction and experimental tools to achieve the precise delivery of mechanical cues to stem cells seeded within a tissue engineering scaffold to direct the stem cell fate. His interest in mechanobiology led him to the respiratory research as a postdoctoral fellow at Bioengineering department of the University of Pennsylvania, developing an in vitro model of ventilator induced lung injury. With his experiences of tissue engineering and barrier tissue modeling, he has developed a vascularized barrier tissue model to study age related macular degeneration, collaborating with NCATS, since he joined a NEI team in 2014. He has held staff scientist position in tissue bioprinting group at NCATS since 2018. His current research is primarily focused on modeling of 3D engineered tissues and relevant diseases for drug development in preclinical studies, using bioprinting technique.

Min Jae Song  Image

3D Modeling of Vascularized Barrier Tissues and Diseases For Preclinical Studies

Friday, 7 October 2022 at 17:30

Add to Calendar ▼2022-10-07 17:30:002022-10-07 18:30:00Europe/London3D Modeling of Vascularized Barrier Tissues and Diseases For Preclinical Studies3D-Bioprinting, Biofabrication, Organoids and Organs-on-Chips Asia 2022 in Tokyo, JapanTokyo,

In vitro three dimensional (3D) cellular models enable the study of multicellular interactions within functional tissue microenvironments. The enhanced physiological relevance of these complex 3D cellular models has opened the possibility of developing human-pathologically relevant disease assays for preclinical drug discovery and development studies. However, the increased cellular and structural complexity of these 3D cellular assays pose a significant technical challenge for their morphological and physiological validation, and use for pharmacological testing. Using 3D bioprinting techniques, we have established a robust and versatile method to engineer human vascularized tissues in a multiwell format. The bioprinting-based approach, used to biofabricate vascularized tissues, included a biodegradable polymer scaffold that enabled the addition of epithelia, in a transwell format. Several human barrier tissue models with vascularization were produced, including skin, peritoneal, and ocular tissues. Once 3D models of “healthy” tissues were biofabricated and validated, disease tissue models were developed by introducing disease-relevant chemical inducers or diseased cells, like cancer cells, into the “healthy” tissues. Treatments of the disease models with FDA approved drugs or drugs in clinical trials were able to correct the disease phenotypes. The structural, functional, and pharmacological validation of these tissues is critical to enable the use of these 3D models to accelerate the drug development process by providing pre-clinical data that it is more predictive of clinical outcomes.

Add to Calendar ▼2022-10-06 00:00:002022-10-07 00:00:00Europe/London3D-Bioprinting, Biofabrication, Organoids and Organs-on-Chips Asia 20223D-Bioprinting, Biofabrication, Organoids and Organs-on-Chips Asia 2022 in Tokyo, JapanTokyo,